Pentagamavunon-1
| 中文名稱 | Pentagamavunon-1 |
|---|---|
| 中文同義詞 | 化合物 PENTAGAMAVUNON-1 |
| 英文名稱 | Pentagamavunon-1 |
| 英文同義詞 | Pentagamavunon-1;Cyclopentanone, 2,5-bis[(4-hydroxy-3,5-dimethylphenyl)methylene]- |
| CAS號 | 27060-70-4 |
| 分子式 | C23H24O3 |
| 分子量 | 348.43 |
| EINECS號 | |
| 相關(guān)類別 | |
| Mol文件 | 27060-70-4.mol |
| 結(jié)構(gòu)式 |  |
Pentagamavunon-1 性質(zhì)
| 沸點 | 562.1±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.232±0.06 g/cm3(Predicted) |
| 儲存條件 | Store at -20°C |
| 溶解度 | 二甲基亞砜：50 mg/mL（143.50 mM） |
| 酸度系數(shù)(pKa) | 10.12±0.40(Predicted) |
| 形態(tài) | 固體 |
| 顏色 | 淺黃至黃色 |
Pentagamavunon-1 (PGV-1) 是Curcumin 的類似物，具有口服活性，通過多個機制誘導(dǎo)凋亡信號，如抑制COX-2 和 VEGF。Pentagamavunon-1 (PGV-1) 可抑制 NF-κB 的激活。
Pentagamavunon-1 (PGV-1, 1, 2.5, 5, 7.5, 10, 15, and 20 μM) enhances cytotoxic effect of 5-FU on WiDr cells.
Pentagamavunon-1 (PGV-1, 1, 2.5, 5, and 10 μM) shows different effects on cell cycle progression and induces G2/M arrest.
Cell Viability Assay.
| Cell Line: | Human colon carcinoma WiDr. |
| Concentration: | 1, 2.5, 5, 7.5, 10, 15, and 20 μM. |
| Incubation Time: | 6, 12, 24, and 48 hours. |
| Result: | Significantly enhanced the cytotoxicity of 5-FU on WiDr cells at various concentrations during 6, 12, 24, and 48 h incubation. |
Cell Cycle Analysis.
| Cell Line: | WiDr cells. |
| Concentration: | 1, 2.5, 5, and 10 μM. |
| Incubation Time: | 24 h. |
| Result: | The non-treated WiDr cells showed cell accumulation in G1, S, and G2/M phase about 50.85%, 36.11% and 13.04%, respectively. |
Pentagamavunon-1 (PGV-1, po, 20 mg/kg) exhibits significant anti-tumor activity in PDX model, without obvious toxicity.
| Animal Model: | Human cancer cells in a xenograf mouse model. |
| Dosage: | 20mg/kg. |
| Administration: | P.O. every 2 days for 20 days. |
| Result: | Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus, PGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells. |
安全信息
| 更新日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
|---|---|---|---|---|---|
| 2025/05/22 | HY-136477 | Pentagamavunon-1 | 27060-70-4 | 5 mg | 600元 |
| 2025/05/22 | HY-136477 | Pentagamavunon-1 Pentagamavunon-1 | 27060-70-4 | 10mM * 1mLin DMSO | 660元 |